Actively Recruiting
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
Led by National Taiwan University Hospital · Updated on 2025-03-20
240
Participants Needed
1
Research Sites
334 weeks
Total Duration
On this page
Sponsors
N
National Taiwan University Hospital
Lead Sponsor
A
Academia Sinica, Taiwan
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\<10 mIU/mL) need to take.
CONDITIONS
Official Title
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 20 years and born after 1987
- Born in Taiwan and completed at least three doses of hepatitis B vaccine in infancy
- Tested negative for hepatitis B surface antibody and surface antigen at baseline
- Never vaccinated against hepatitis B during childhood and adolescence by questionnaire
- Consent to receive 1 or 2 doses of hepatitis B vaccine according to group assignment
- In good health
You will not qualify if you...
- Allergy to hepatitis B vaccine or its components (such as yeast)
- Vaccinated against hepatitis B during childhood or adolescence
- Positive test for hepatitis B surface antibody or surface antigen
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Family Medicine, NTUH
Taipei, Taiwan, 100
Actively Recruiting
Research Team
C
CHYI-FENG JAN, MD, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here